View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 26, 2021updated 12 Jul 2022 11:18am

Biological E. to begin Phase III Covid-19 vaccine candidate trial 

Indian company Biological E. is set to launch the Phase III clinical trial of its Covid-19 subunit vaccine candidate after obtaining the Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee (SEC) approval.

Indian company Biological E. is set to launch the Phase III clinical trial of its Covid-19 subunit vaccine candidate after obtaining the Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee (SEC) approval.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The vaccine candidate has an antigen developed by the Texas Children’s Hospital Center for Vaccine Development and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialisation team, and Dynavax Technologies’ advanced adjuvant, CpG 1018TM.

The Phase III trial will be carried out at 15 sites in India to analyse if the immunogenicity and safety of the vaccine can provide protection against Covid-19. It will enrol approximately 1,268 healthy subjects aged between 18 and 80.

It is anticipated to be part of a larger global Phase III study.

The latest move comes after the company successfully concluded the Phase I/II trial of the vaccine candidate, which began in India in November last year.

Data from the Phase I/II trial showed that the Covid-19 vaccine was safe, well-tolerated, and immunogenic.

Biological E. managing director Mahima Datla said: “We are delighted with the success of the Phase I/II clinical trials of our Covid-19 vaccine candidate. The results of these clinical trials are very positive and promising.

“We believe that our vaccine candidate will become another effective global Covid-19 vaccine as we move forward into Phase III clinical trials.”

In another development, Inovio has announced plans to conduct a Phase III trial for its Covid-19 vaccine candidate INO-4800 outside the US.

The Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) along with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA) have decided to stop funding for the Phase III segment of the INNOVATE trial owing to the increased availability of several vaccines authorised for emergency use.

They continue to provide funds to conclude the ongoing Phase II segment.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena